India, Aug. 7 -- Zydus Lifesciences (including its subsidiaries/ affiliates, hereafter referred to as 'Zydus') has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group's first NOC approval in Canada.Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.ZDS-Varenicline tablets will be produced at Zydus Lifescience, SEZ, Ahmedabad. Varenicline tablets had annual sales of 15 mn Canadian dollar in Canada (IQVIA MAT December 2024).
Published by HT Digital Content Services with permission from Pivotal Sources....